{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:58:29Z","timestamp":1783699109250,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lymph node metastasis is the major cause of increased recurrence and death in patients with papillary thyroid carcinoma (PTC). We evaluate the clinicopathologic factors affecting excellent response (ER) in patients with PTC with lymph node metastasis following operation and <jats:sup>131<\/jats:sup>I ablation therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 423 patients with PTC with lymph node metastasis who underwent thyroidectomy and postoperative <jats:sup>131<\/jats:sup>I ablation therapy were enrolled. The relationship between clinicopathological factors affecting ER achievement was analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Multivariate analysis showed that the foci diameter (\u22641 cm), unifocal, combination with Hashimoto\u2019s thyroiditis (HT), lymph node metastases rate (LR) (\u226440%), no postoperative lymph node metastasis, low preablative stimulated thyroglobulin (ps-Tg) level (\u22643.87 ng\/mL), and the time of <jats:sup>131<\/jats:sup>I ablation therapy (one time) were positively correlated with the ER achievement [odds ratio (OR): 1.744, 3.114, 3.920, 4.018, 2.074, 9.767, and 49.491, respectively; all <jats:italic>p<\/jats:italic> &amp;lt; 0.05]. The receiver operating characteristic (ROC) curves showed that the cutoff values of ps-Tg and LR were 4.625 ng\/mL and 50.50%, respectively. The AUC of ROC of ps-Tg and LR for predicting ER achievement was 0.821 and 0.746, respectively. The Tg and the cumulative risk of non-ER elevated with the increase of LR, especially for the high-level ps-Tg (&amp;gt;4.625 ng\/mL) group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The foci diameter and number, combination with HT, LR, and ps-Tg level are independent factors for ER. Ps-Tg level and LR are valid predictive factors for the efficacy of <jats:sup>131<\/jats:sup>I therapy in patients with PTC. The predictive value of the cumulative risk of non-ER can be improved by the combination of ps-Tg and LR.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1382009","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T04:27:03Z","timestamp":1721190423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinicopathological features affecting the efficacy in 131I ablation therapy of papillary thyroid carcinoma with lymph node metastasis"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiwen","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.surg.2003.08.023","article-title":"Prognostic factors in papillary thyroid carcinoma and implications of large nodal metastasis","volume":"135","author":"Shaha","year":"2004","journal-title":"Surgery"},{"key":"B2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/cncr.11442","article-title":"Papillary microcarcinoma of the thyroid\u2014Prognostic significance of lymph node metastasis and multifocality","volume":"98","author":"Chow","year":"2003","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0232","article-title":"In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response","volume":"21","author":"Vaisman","year":"2011","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0372","article-title":"Application of molecular biology of differentiated thyroid cancer for clinical prognostication","volume":"23","author":"Marotta","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2555","article-title":"Germline polymorphisms of the VEGF pathway predict recurrence in nonadvanced differentiated thyroid cancer","volume":"102","author":"Marotta","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00177","article-title":"Risk stratification in differentiated thyroid cancer: from detection to final follow-up","volume":"104","author":"Tuttle","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1015798","article-title":"Analysis of factors influencing the clinical outcome after surgery and 131I therapy in patients with moderate-risk thyroid papillary carcinoma","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00640","article-title":"Efficacy and affecting factors of 131I thyroid remnant ablation after surgical treatment of differentiated thyroid carcinoma","volume":"8","author":"Wang","year":"2018","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0219","article-title":"TSH \u226530 mU\/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer","volume":"12","author":"Ju","year":"2023","journal-title":"Eur Thyroid J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"Cooper","year":"2009","journal-title":"Thyroid"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American joint committee on cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth edition): what changed and why","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1097-0142","article-title":"The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth edition American Joint Committee on Cancer staging, proximal disease, and the \u201cdifferent disease\u201d hypothesis","volume":"88","author":"Hundahl","year":"2000","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3390\/ijms18081817","article-title":"Current advances in thyroid cancer management. Are we ready for the epidemic rise of diagnoses","volume":"18","author":"Rusinek","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0077","article-title":"Low recurrence rates in a cohort of differentiated thyroid carcinoma patients: A referral center experience","volume":"25","author":"Scheffel","year":"2015","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.899028","article-title":"Iodine-131: an effective method for treating lymph node metastases of differentiated thyroid cancer","volume":"22","author":"He","year":"2016","journal-title":"Med Sci Monitor Int Med J Exp Clin Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2835496\/v1","article-title":"Guiding the postoperative radioactive iodine-131 therapy for patients with papillary thyroid carcinoma according to the prognostic risk groups: a SEER-based study","volume":"149","author":"Yang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.20945\/2359-3997000000538","article-title":"Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer","volume":"67","author":"Gao","year":"2023","journal-title":"Arch Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001167","article-title":"In patients with low- to intermediate-risk thyroid cancer, a preablative thyrotropin level of 30 \u03bcIU\/mL is not adequate to achieve better response to 131I therapy","volume":"41","author":"Zhao","year":"2016","journal-title":"Clin Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.155086","article-title":"Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer","volume":"128","author":"Yang","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12282","article-title":"Thyroglobulin as early prognostic marker topredict remission at 18\u201324 months in differentiated thyroid carcinoma","volume":"80","author":"Gonzalez","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.644645","article-title":"Influencing factors and cumulative risk analysis of cervical lymph node metastasis of papillary thyroid microcarcinoma","volume":"11","author":"Yin","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-018-01321-w","article-title":"Impact factors for the outcome of the first 131I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy","volume":"33","author":"Shangguan","year":"2018","journal-title":"Ann Nucl Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/cancers13020310","article-title":"The prognostic role of postablative non-stimulated thyroglobulin in differentiated thyroid cancer","volume":"13","author":"Szujo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20209781","article-title":"A cutoff thyroglobulin value suggestive of distant metastases in differentiated thyroid cancer patients","volume":"53","author":"Couto","year":"2020","journal-title":"Braz J Med Biol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0903","article-title":"The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis","volume":"168","author":"Lee","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1149","article-title":"Coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma. A retrospective study","volume":"9","author":"Mazokopakis","year":"2010","journal-title":"Hormones (Athens Greece)"},{"key":"B28","first-page":"1","article-title":"The association between papillary carcinoma and chronic lymphocytic thyroiditis: does it modify the prognosis of cancer","volume":"33","author":"Del","year":"2008","journal-title":"Minerva Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.801925","article-title":"Hashimoto's thyroiditis: A \"Double-edged sword\" in thyroid carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13000-019-0832-2","article-title":"IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis","volume":"14","author":"Han","year":"2019","journal-title":"Diagn Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840811","article-title":"Single-cell transcriptome analysis reveals inter-tumor heterogeneity in bilateral papillary thyroid carcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1185-1","article-title":"Chronic lymphocytic thyroiditis does not influence the risk of recurrence in patients with papillary thyroid carcinoma and excellent response to initial therapy","volume":"55","author":"Carvalho","year":"2017","journal-title":"Endocrine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2012.27.8.883","article-title":"Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome","volume":"27","author":"Jeong","year":"2012","journal-title":"J Korean Med Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0053","article-title":"Impact of thyroiditis on 131I uptake during ablative therapy for differentiated thyroid cancer","volume":"8","author":"Lim","year":"2019","journal-title":"Endocrine connections"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0052","article-title":"A prospective multicenter study examining the relationship between thyroid cancer treatment outcomes and the presence of autoimmune thyroiditis","volume":"33","author":"De Leo","year":"2023","journal-title":"Thyroid"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1382009\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T04:27:10Z","timestamp":1721190430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1382009\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":35,"alternative-id":["10.3389\/fendo.2024.1382009"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1382009","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"article-number":"1382009"}}